Close Menu

NEW YORK – Clinical-stage precision medicine company MapKure and its joint owners BeiGene and SpringWorks Therapeutics said Thursday that they have kicked off a Phase I clinical trial evaluating BGB-3245, an investigational BRAF inhibitor. 

The trial will enroll up to 69 patients with solid tumors who harbor BRAF mutations and are likely to respond to a RAF dimer inhibitor. The companies have dosed their first patient in Australia and will soon expand the study to sites in the US.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.